

As cancer becomes one of the leading causes of mortality across Asia, the medical community is shifting from a “treat when sick” approach to a “prevent and detect early” mindset. This shift is driven by a new method called MCED – Multi-Cancer Early Detection, also known as multi-cancer screening via a single blood test.
Unlike annual check-ups or traditional cancer screenings that target one organ at a time, MCED can detect signals of multiple cancers simultaneously, even before symptoms appear.
This matters because many cancers common in Asia such as liver, lung, pancreatic, gastrointestinal, and head & neck cancers tend to stay silent for 3–5 years, making them difficult to detect through ultrasound, CT scans, or routine blood tests.

Families choose LucenceInsight because it offers:
✓ Screening for up to 50 types of cancer
✓ Ability to detect cancer signals even before symptoms
✓ One simple blood draw
✓ Analytical accuracy up to 99% (ctDNA)
✓ Designed to focus on high-risk Asian cancers
LucenceInsight is developed by Lucence (USA) with a scientific team trained at Stanford, and clinical interpretation aligned with data and guidance from Mayo Clinic (USA) - one of the top cancer and surgical centers in the world.

Beyond the underlying technology, the laboratory itself plays a critical role in ensuring the reliability of test results. The laboratory performing the test meets international standards such as CAIL and CAP, both of which are long-established and highly respected certifications assessed directly by the College of American Pathologists (CAP) in the United States. At present, only a limited number of laboratories in countries with advanced healthcare systems and stringent quality-control requirements are able to achieve both certifications simultaneously, reflecting a high level of operational capability, data governance, and clinical accuracy in line with international standards.
In addition, Lucence's testing process is designed to be patient-friendly and minimally invasive: no fasting — no anesthesia — no pain — no symptoms required.
LucenceINSIGHT™ uses advanced liquid biopsy technology to detect genomic changes associated with up to 50 types of cancer, offering broad coverage in a single screening.
The screening process requires only one simple blood draw, making it a convenient and minimally invasive option for those seeking proactive cancer detection.
Once your blood sample is collected, results are typically available within 12 to 18 days, allowing for timely discussion and follow-up with Wonderhealth.
Adults 30–75 years old, especially: parents, people with family history of cancer, HBV, smokers, heavy drinkers, those under high stress, or anyone who goes for annual check-ups but wants deeper cancer screening.
Check if MCED is suitable for your family
In Vietnam, 70–80% of cancer cases are detected late, even among people who do annual check-ups. Not because healthcare is poor, but because:
MCED addresses this gap by detecting cancer DNA signals in the blood, even when imaging looks normal and before symptoms appear.
(According to National Cancer Institute, adults aged 65 and above account for over 60% of all cancer diagnoses)
When cancer is found early, doctors have more treatment options, lower costs, and higher success rates.
Late-stage cancer is what becomes “expensive”:
Early detection helps you:
✓ Reduce financial risk
✓ Keep better treatment options on the table
✓ Keep parents healthier for longer
Get Free Screening Advice for Parents
If 1 out of 5 answers is “Yes”, you should request a free consultation with our patient assistance specialist.
Get Your Consultation Within 24 Hours
Vietnamese patients can access LucenceInsight through a specialist medical journey in Singapore, which includes:
✓ LucenceInsight testing
✓ Consultation with a health screening doctor
✓ Personal health file analysis
✓ Follow-up guidance & prevention planning

This is no longer about “going to Singapore for treatment” — it’s about:
going to Singapore so you don’t need treatment later.